U.S. Department of Health & Human Services
National Institutes of Health
NCATS
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
AGALSIDASE BETA
RZD65TSM9U
US Approved Rx (2003)
First approved in 2003
General
Record Details
Names
12
Classification
7
Identifiers
15
Subunits
2
Relationships
1
Active Moiety
1
Characteristic Attributes
3
AGALSIDASE BETA
RZD65TSM9U
US Approved Rx (2003)
First approved in 2003
General
Approval Year
2003
176
Record Details
Substance Class
Protein
Protein Sub Type
Sequence Origin
HUMAN
Sequence Type
COMPLETE
Record UNII
RZD65TSM9U
Record Status
Validated (UNII)
Record Version
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
Names
12
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
AGALSIDASE BETA
Official Name
English
AGALSIDASE BETA [VANDF]
Common Name
English
AGALSIDASE BETA [PURPLE BOOK CDER]
Common Name
English
AGALSIDASE BETA (GENETICAL RECOMBINATION)
Common Name
English
agalsidase beta [INN]
Common Name
English
Showing 1 to 5 of 12 entries
Previous
1
2
3
Next
Classification
7
Show
5
20
100
All
entries
Classification Tree
Code System
Code
Classification Tree
Code System
Code
SPHINGOLIPIDOSES
EMA EPAR
DISEASES
NERVOUS SYSTEM DISEASES
CENTRAL NERVOUS SYSTEM DISEASES
BRAIN DISEASES
BRAIN DISEASES, METABOLIC
BRAIN DISEASES, METABOLIC, INBORN
LYSOSOMAL STORAGE DISEASES, NERVOUS SYSTEM
SPHINGOLIPIDOSES
FABRY DISEASE
EMA ASSESSMENT REPORTS
FABRAZYME (AUTHORIZED: FABRY DISEASE
Enzymes
VATC
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
Enzymes
agalsidase beta
WHO-VATC
QA16AB04
Designated/Approved
ORPHAN DRUG
Designated/Approved
Treatment of Fabry's disease.
FDA ORPHAN DRUG
15286
Biological Agent
Pharmacologic Substance
[C1909]
Biological Agent
[C307]
Enzyme Replacement or Supplement Agent
NCI_THESAURUS
C29726
Established Pharmacologic Class
Established Pharmacologic Class
[EPC]
Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme
[EPC]
NDF-RT
N0000175822
Showing 1 to 5 of 7 entries
Previous
1
2
Next
Identifiers
15
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
USAN
LL-45
PRIMARY
EVMPD
SUB12457MIG
PRIMARY
LACTMED
Agalsidase Beta
PRIMARY
DAILYMED
RZD65TSM9U
PRIMARY
DRUG BANK
DB00103
PRIMARY
Showing 1 to 5 of 15 entries
Previous
1
2
3
Next
Subunits
2
Relationships
1
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
3U2455CVM6
ISARALGAGENE CIVAPARVOVEC
VECTOR->EXPRESSED PROTEIN
Amount:
Showing 1 to 1 of 1 entries
Previous
1
Next
Active Moiety
1
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
RZD65TSM9U
AGALSIDASE BETA
ACTIVE MOIETY
Showing 1 to 1 of 1 entries
Previous
1
Next
Characteristic Attributes
3
Name
Property Type
Amount
Referenced Substance
Defining
Parameters
References
Biological Half-life
PHARMACOKINETIC
[45 to 102] minutes (average)
Molecular Formula
CHEMICAL
ESTIMATED
C4058H6120N1088O1174S54
MOL_WEIGHT:APPROXIMATE
CHEMICAL
APPROXIMATE 90702.9 Da (average)
